AtriCure, Inc. (NASDAQ:ATRC) Insider Sells $55,080.00 in Stock

AtriCure, Inc. (NASDAQ:ATRCGet Free Report) insider Justin J. Noznesky sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $36.72, for a total transaction of $55,080.00. Following the sale, the insider now owns 74,284 shares in the company, valued at approximately $2,727,708.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

AtriCure Stock Performance

ATRC stock opened at $32.14 on Friday. The company has a quick ratio of 2.66, a current ratio of 3.57 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -48.70 and a beta of 1.39. AtriCure, Inc. has a 12 month low of $29.67 and a 12 month high of $59.61. The firm has a 50 day moving average of $34.12 and a two-hundred day moving average of $37.08.

AtriCure (NASDAQ:ATRCGet Free Report) last posted its earnings results on Thursday, February 15th. The medical device company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.01. The company had revenue of $106.50 million during the quarter, compared to the consensus estimate of $103.68 million. AtriCure had a negative net margin of 7.62% and a negative return on equity of 7.55%. The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.09) earnings per share. As a group, equities analysts anticipate that AtriCure, Inc. will post -0.71 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ATRC. UBS Group boosted their price target on shares of AtriCure from $57.00 to $58.00 and gave the company a “buy” rating in a report on Friday, February 16th. StockNews.com lowered shares of AtriCure from a “hold” rating to a “sell” rating in a report on Monday, February 19th. Needham & Company LLC boosted their price target on shares of AtriCure from $44.00 to $46.00 and gave the company a “buy” rating in a report on Friday, February 16th. JMP Securities reiterated a “market outperform” rating and issued a $60.00 price objective on shares of AtriCure in a research note on Wednesday, November 29th. Finally, Stifel Nicolaus dropped their price objective on shares of AtriCure from $50.00 to $42.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.57.

Read Our Latest Analysis on AtriCure

Institutional Trading of AtriCure

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in AtriCure by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 4,766,029 shares of the medical device company’s stock worth $170,100,000 after acquiring an additional 76,146 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of AtriCure by 1.5% during the 2nd quarter. BlackRock Inc. now owns 3,914,792 shares of the medical device company’s stock worth $193,234,000 after buying an additional 58,501 shares during the period. Alliancebernstein L.P. boosted its holdings in shares of AtriCure by 2.8% during the 2nd quarter. Alliancebernstein L.P. now owns 3,209,989 shares of the medical device company’s stock worth $158,445,000 after buying an additional 86,485 shares during the period. Invesco Ltd. boosted its holdings in shares of AtriCure by 17.5% during the 1st quarter. Invesco Ltd. now owns 2,865,409 shares of the medical device company’s stock worth $188,171,000 after buying an additional 427,792 shares during the period. Finally, Macquarie Group Ltd. boosted its holdings in shares of AtriCure by 2.4% during the 1st quarter. Macquarie Group Ltd. now owns 1,409,302 shares of the medical device company’s stock worth $58,416,000 after buying an additional 33,348 shares during the period. 94.30% of the stock is owned by institutional investors.

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

Read More

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.